Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Sermorelin29 residuesYADAIFTNSYRKVLGQLSARKLLQDIMSREach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Geref, GRF 1-29, GHRH(1-29)NH2
FDA-approved in 1997 and voluntarily withdrawn in 2008 for manufacturing reasons, not safety. The sermorelin peptide (Geref) is the first 29 amino acids of endogenous growth hormone releasing hormone (GHRH), the biologically active fragment that fully retains pituitary GHRH receptor binding. Vittone et al. [1] confirmed improved body composition, raised IGF-1, and better sleep architecture in age-advanced adults over six months of daily subcutaneous dosing. Antibody formation in roughly 70% of continuous users at 18 months is the primary long-term concern, and cycling mitigates it. Adults over 30 seeking the most conservative, best-studied GH secretagogue start here.
Twenty-nine amino acids. That's what separates the sermorelin peptide (also known as Geref or GRF 1-29) from the full 44-amino-acid endogenous GHRH molecule, and those 29 amino acids are the only ones that matter for receptor binding. Sermorelin acetate (CAS 86168-78-7) is a synthetic analog of human GHRH(1-29)NH2 that retains complete GHRH receptor affinity on pituitary somatotroph cells. The mechanism is direct. Sermorelin binds the GHRH receptor, triggering pulsatile GH release that mirrors the body's natural secretion pattern. Unlike exogenous growth hormone injections, this preserves the hypothalamic-pituitary feedback loop. The pituitary decides how much GH to release; sermorelin just gives it a stronger signal to do so. That distinction matters for long-term safety. Vittone and colleagues ran a six-month trial in age-advanced adults [1] using once-daily subcutaneous GHRH analog injections. The results landed on lean mass gains, fat reduction, and improved sleep architecture. The Geref International Study Group [2] confirmed sustained growth velocity in GH-deficient children at 30 mcg/kg/day over 12 to 36 months. Subcutaneous bioavailability sits at approximately 6% per the Geref product label, which is expected for GHRH analogs and still produces reliable pharmacological GH pulses. In practice, sermorelin is the "start here" peptide on r/Peptides (roughly 95,000 subscribers). Community dosing runs 200 to 300 mcg nightly, almost always co-injected with ipamorelin for dual-pathway GH release. Sleep improvement within the first two weeks is the most consistently reported early effect across hundreds of threads. Body composition shifts require two to three months of patience. No new large RCTs for anti-aging indications have been published between 2024 and 2026, so the adult off-label evidence base relies on the 1990s clinical data combined with a large, consistent community experience. Compared to CJC-1295 (No DAC), sermorelin has a shorter half-life (10 to 20 minutes versus roughly 30 minutes) but decades more clinical safety data, including FDA approval history from 1997 to 2008. CJC-1295 has zero completed human trials for anti-aging indications.
Sermorelin binds the growth hormone releasing hormone receptor (GHRH-R) on anterior pituitary somatotroph cells. This is the same receptor that endogenous GHRH activates to trigger natural GH secretion. The 1-29 amino acid fragment retains full receptor binding affinity because the N-terminal portion of GHRH contains all the structural elements needed for GHRH-R recognition and activation. Once GHRH-R activates, it triggers intracellular cyclic AMP signaling in somatotrophs. That cascade opens calcium channels, prompting GH vesicle release into circulation. The resulting GH pulse peaks at approximately 30 to 60 minutes post-injection and clears quickly; sermorelin's plasma half-life is only 10 to 20 minutes subcutaneously (roughly 6 to 7 minutes intravenously per the Geref product label). The short half-life is actually a feature. It produces a discrete pulse rather than sustained tonic GH elevation, preserving the natural pulsatile secretion rhythm. The downstream chain follows a predictable path. Pulsatile GH stimulates hepatic IGF-1 synthesis, and IGF-1 mediates most of the tissue-level effects: protein synthesis, lipolysis, collagen production, and bone metabolism. Because sermorelin works through the pituitary rather than replacing GH directly, the hypothalamic feedback loop stays intact. Somatostatin still is the natural brake on GH secretion. This self-limiting mechanism is why supraphysiological GH levels are uncommon with sermorelin at standard doses. The antibody issue is worth understanding mechanistically. Sermorelin is a foreign peptide analog. Repeated daily injection triggers an adaptive immune response in approximately 70% of patients by 18 months of continuous dosing (Geref prescribing information). These anti-sermorelin antibodies neutralize the peptide before it reaches the GHRH receptor. Cycling reduces total antigen exposure and slows immune sensitization.
Mechanism well-established: sermorelin is the 1–29 N-terminal fragment of endogenous GHRH, fully retaining GHRH receptor (GHRH-R) binding activity and stimulating pulsatile GH release from the pituitary somatotrophs. FDA-approved 1997 (Geref) for GH deficiency diagnosis and pediatric GH deficiency treatment; voluntarily discontinued 2008 for manufacturing reasons, not safety. Multiple RCTs in pediatric and adult GH deficiency confirm efficacy. Vittone et al. 1997 [1] demonstrated improved body composition, increased IGF-1, and improved sleep in age-advanced adults. Antibody formation (~70% of patients at 18 months continuous dosing per Geref label) is the primary long-term efficacy concern. No new large RCTs published 2024–2026 for anti-aging off-label indications.
Vittone et al. 1997 (PMID 9141536): 6-month once-daily SC GHRH analog in age-advanced adults showed significant IGF-1 elevation, improved body composition (lean mass gain, fat reduction), and improved sleep architecture. Geref International Study Group (PMID 8772599): 30 mcg/kg/day SC in GH-deficient children; growth velocity sustained 12–36 months.
Most definitive RCTs conducted 1990s–2000s; no large modern RCT specifically for adult anti-aging or body composition indications. Off-label dosing (200–500 mcg adult) is community-derived, not established by an RCT. Antibody formation data from the original Geref label (pre-2008): long-term antibody impact in current compounded formulations not re-studied. SC bioavailability ~6% (expected for GHRH analogs).
Widely regarded as the most conservative, beginner-appropriate GH secretagogue. "Start here before CJC/Ipa" is the dominant consensus. Primary uses: sleep optimization, anti-aging, modest body recomposition. Nearly always stacked with ipamorelin for synergistic GHRH + GHRP dual-pathway GH release.
Science and community agree on GHRH-R mechanism, pulsatile GH release, and SC nightly dosing. Community dosing range (200–300 mcg nightly) is consistent with the clinical adult dosing range. Bedtime administration, empty stomach requirement, and 5-day cycling are all mechanistically grounded in published pharmacology. Primary divergence: community almost always stacks sermorelin with ipamorelin while clinical trials tested sermorelin monotherapy. Antibody formation concern is present in both clinical data and community experience.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mcg | Daily |
| Moderate | 300mcg | Daily |
| Aggressive | 500mcg | Daily |
With a 5 mg vial and 2 mL bacteriostatic water, you get 2,500 mcg/mL. At that concentration: 200 mcg is 8 units on a U-100 insulin syringe, 300 mcg is 12 units, and 500 mcg is 20 units. The fasting window is where most beginners fail. You need at least two hours with no food before the injection. Insulin triggers somatostatin release from the hypothalamus, which directly opposes GH secretion. Eating within that window doesn't just reduce the effect; it negates it. Bedtime dosing is the priority. Sermorelin amplifies the natural nocturnal GH pulse during slow-wave sleep. Inject 30 to 60 minutes before sleep for best results. Store reconstituted vials at 2 to 8 degrees Celsius. Discard anything cloudy or with visible particles. Lyophilized powder is more stable but still belongs in the fridge. If you see no sleep improvement after two weeks with correct timing, check your reconstitution math first. Then get an IGF-1 draw at week six. If IGF-1 isn't moving, suspect the product quality before blaming the peptide. Most users stack sermorelin with ipamorelin. The two hit different receptor pathways (GHRH-R and GHS-R1a) and produce a synergistic GH pulse larger than either alone.
The Geref prescribing information documents that approximately 70% of patients on continuous daily sermorelin develop anti-sermorelin antibodies at 18 months. These antibodies bind sermorelin and neutralize its GHRH-R activity, progressively reducing GH-stimulating efficacy. The antibody response is driven by repeated antigen exposure. Cycling (5-days-on/2-days-off and periodic 4-week breaks) reduces total antigen exposure, mitigates immune sensitization, and helps maintain long-term pituitary responsiveness.
Or use the universal Peptide Calculator for any peptide.
Expected: Improved sleep quality (weeks 1–2), better recovery (weeks 3–4), modest lean mass gain and fat loss (months 2–3), improved skin quality (months 3+)
Monitor: IGF-1 baseline, week 6, month 3, month 6. Fasting glucose baseline and every 3 months. Thyroid panel at baseline (hypothyroidism blunts GH response).
Neuroscientist & Stanford Professor
I stopped taking it because REM depletion was something I didn't want.
Pull 2 mL of bacteriostatic water into a 29 to 31 gauge insulin syringe. For a 5 mg vial, this gives 2,500 mcg per mL. Let the water run slowly down the inside wall of the vial. Never spray directly onto the lyophilized powder. Swirl gently until fully dissolved.
At 2,500 mcg/mL (5 mg vial + 2 mL BAC water): 200 mcg = 8 units, 300 mcg = 12 units, 500 mcg = 20 units on a U-100 insulin syringe.
Minimum two hours since your last meal. No food for 30 minutes after injection, either.
Abdomen (periumbilical area, avoiding the navel) or lateral thigh. Rotate sides with each injection.
Insert the needle at a 45-degree angle. Inject slowly and hold for five seconds before withdrawing. Use a 27 to 31 gauge, 5/16 inch or 3/8 inch needle.
If stacking with ipamorelin, draw sermorelin first, then ipamorelin into the same syringe. Co-inject at the same site and time. For a typical beginner stack: 8 units sermorelin (200 mcg from a 5 mg/2 mL vial) plus 20 units ipamorelin (200 mcg from a 2 mg/2 mL vial).
Store the reconstituted vial in the refrigerator immediately after use.
Cycling: 5 days on, 2 days off (for example, Monday through Friday). Take a full four-week break after each three-to-six-month cycle to prevent antibody formation.
Reference route; all published dosing data based on SC administration
SC bioavailability ~6% (Geref label). Despite low absolute bioavailability, SC reliably produces pharmacological GH pulses. Inject into abdomen (periumbilical) or lateral thigh fat, rotating sites. 27–31G 5/16" or 3/8" insulin needle standard.
Bioavailability unknown: no PK study comparing sublingual vs. SC sermorelin published as of April 2026. Tablets marketed at $79–$139/month; dose equivalence to SC injection unestablished.
Sublingual sermorelin tablets are now available through some telehealth platforms (e.g., bmiMD). Sermorelin is a 29-amino-acid peptide: sublingual absorption of intact peptides is generally low due to protease activity and mucosal impermeability. Patients should understand this is an unvalidated route with no comparative efficacy data vs. the clinically established SC route.
Intranasal bioavailability for GHRH analogs estimated ~20% of SC in limited studies; sermorelin-specific intranasal PK data not published
Not a standard clinical or commercial route for sermorelin. Some compounding pharmacies have prepared intranasal formulations but this is not supported by published efficacy data for sermorelin specifically.
Gold-standard dual-pathway stack. Ipamorelin (GHS-R1a / GHRP) amplifies the GH pulse initiated by sermorelin (GHRH-R) via a complementary receptor pathway. Produces a larger, more physiological GH pulse than either alone. Ipamorelin adds selectivity: no cortisol, prolactin, or appetite elevation.
200 mcg sermorelin + 200 mcg ipamorelin co-injected SC, 30–60 min before sleep
Added for systemic recovery, gut health, and injury healing while sermorelin handles GH optimization. No direct pharmacokinetic interaction. Injected separately at a different site and timing.
BPC-157 250–500 mcg SC separate injection, separate site; timing flexible
Added to sermorelin protocols for enhanced tissue repair and anti-inflammatory effects, particularly in athletes. GH optimization (sermorelin) + systemic healing (TB-500) is a popular body recomposition stack.
TB-500 2–5 mg SC 1–2× per week; separate injection from sermorelin
Both are GHRH-R agonists: concurrent use is redundant and provides receptor competition without additive benefit. Tesamorelin is significantly more potent; combining does not amplify effect. Choose one GHRH analog per cycle.
Do not combineCJC-1295 DAC produces a prolonged continuous GHRH signal (t½ ~7 days) that is mechanistically incompatible with sermorelin's pulsatile GHRH approach. The DAC formulation blunts GH pulsatility that sermorelin is designed to optimize. Concurrent use is counterproductive and redundant.
Do not combineChronic glucocorticoid use blunts pituitary GH secretion and reduces the IGF-1 response to sermorelin. Documented in the Geref prescribing information as a drug interaction. Short-course steroids have minimal impact; chronic use substantially reduces sermorelin efficacy.
Somatostatin analogs directly suppress GH release from pituitary somatotrophs: pharmacologically opposing sermorelin's mechanism. Concurrent use eliminates sermorelin efficacy.
Do not combinePricing updated 2026-04-09
Antibody formation is the primary long-term safety concern with sermorelin. The Geref prescribing information documents that approximately 70% of patients on continuous daily dosing develop anti-sermorelin antibodies by 18 months. These antibodies neutralize the peptide and progressively reduce its ability to stimulate GH release. This isn't a minor footnote. Users who skip cycling and run sermorelin continuously for six-plus months commonly report complete loss of effect. The antibody response is antigen-driven, so reducing injection frequency (5 days on, 2 days off) and taking periodic four-week breaks are the established mitigation strategies. Facial flushing is the most common acute side effect. It typically occurs 20 to 30 minutes after injection and results from the vasodilatory response to acute GH release. Community reports and clinical data both describe this as transient, resolving within an hour, and most prominent during the first one to three weeks of use. It does not require dose adjustment unless severe. Headache and dizziness post-injection are reported at moderate frequency. Like flushing, these relate to the acute GH pulse. They tend to resolve by weeks three to four without intervention. If persistent, reducing the dose by 50 mcg usually handles it. Injection-site reactions (redness, minor irritation, occasional nodules) are expected with any subcutaneous peptide. Consistent site rotation and allowing refrigerated peptide to reach room temperature before injecting both reduce incidence. Nodules persisting beyond one week warrant switching to a different anatomical region. GH-mediated insulin resistance is a theoretical concern with any GH-raising therapy. Sermorelin produces physiological (not supraphysiological) GH pulses, so the risk is lower than with exogenous GH. Still, fasting glucose monitoring every three months is appropriate, especially for anyone over 40 or carrying metabolic risk factors. A fasting glucose above 126 mg/dL means stopping. GH promotes cell proliferation. Active cancer, a history of malignancy, or active pituitary tumors are absolute contraindications. If IGF-1 surpasses the age-adjusted upper normal range, the dose should be reduced or the protocol discontinued. Untreated hypothyroidism impairs GH response to sermorelin (Geref contraindications). GH also accelerates T4-to-T3 conversion, so thyroid function may shift during use. Baseline thyroid panel is recommended. Pregnancy and breastfeeding are contraindicated. Effects on fetal development have not been established. When to see a doctor: persistent edema, fasting glucose above 126 mg/dL, joint pain unresponsive to dose reduction, symptoms of intracranial hypertension, or any sign of glucose intolerance.
Verify Sermorelin dosing and safety with a second opinion
Sermorelin has a USP monograph and is legally compoundable through licensed 503A/503B pharmacies in the US: a meaningful quality advantage over research-chemical peptides. However, as a compounded (not FDA-manufactured) product, GMP compliance, sterility, and potency are pharmacy-dependent and unverified by FDA. Grey-market research chemical vials exist and carry substantially higher contamination and misdosing risk.
| Test | When | Target |
|---|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | Baseline; week 6; month 3; month 6; after each cycling restart | Age- and sex-adjusted mid-normal range (typically 150–300 ng/mL in adults 30–60; labs provide age-specific reference ranges) |
| Fasting glucose | Baseline; every 3 months during use | Fasting glucose <100 mg/dL normal; 100–125 prediabetic (consider dose reduction); ≥126 mg/dL (stop) |
| Thyroid panel (TSH, Free T3, Free T4) | Baseline; repeat if symptoms emerge or if IGF-1 fails to rise | TSH 0.5–4.5 mIU/L; Free T4 and Free T3 within laboratory reference range |
| HbA1c | Baseline; every 6 months (every 3 months if >45 years, overweight, or family history of T2DM) | <5.7% normal; 5.7–6.4% prediabetes (reduce dose, increase monitoring); ≥6.5% (stop) |
Primary biomarker for GH axis activity. Tracks cumulative 24-hour GH output. Supranormal IGF-1 indicates dose is too high.
GH induces insulin resistance. Sermorelin produces physiological (not supraphysiological) GH pulses, but fasting glucose monitoring is appropriate for any GH-elevating therapy, especially in individuals over 40 or with metabolic risk factors.
Untreated hypothyroidism significantly impairs GH response to sermorelin (Geref contraindications). GH can also accelerate T4→T3 conversion: thyroid function may shift with prolonged GH elevation.
Long-term glycemic impact assessment. Less acute than fasting glucose but reflects 3-month average; appropriate for longer cycles.
Improved sleep depth and quality often noticed first. Mild facial flushing may occur around injection time. GH pulses begin to normalize.
Recovery between workouts improves. Energy and mood stabilize. Skin hydration begins to improve as IGF-1 levels rise.
Body composition shifts become measurable: modest fat loss, improved muscle tone. Hair and nail growth may accelerate. Joint comfort improves.
Peak benefits for body composition, sleep, and recovery. IGF-1 levels plateau at new baseline. Skin thickness may increase based on clinical data.
Benefits are sustained with continued use. Periodic IGF-1 monitoring recommended. Some practitioners cycle 5 days on, 2 days off to maintain pituitary sensitivity.
Weeks 1 to 2: GH pulse normalization begins within days of the first injection. Pituitary somatotrophs need roughly one to two weeks of repeated GHRH-R stimulation to upregulate secretory capacity. Plasma IGF-1 starts climbing. Sleep is the first thing most users notice, usually within the first week. Deeper onset, longer slow-wave phases, vivid dreams. Mild facial flushing 20 to 30 minutes post-injection is common and expected. Light headache and brief dizziness may accompany the flush. Both resolve as the body adjusts. Weeks 3 to 4: IGF-1 becomes measurably raised above baseline. Recovery between workouts picks up. Reduced muscle soreness and more stable daytime energy are the consistent community reports at this stage. Skin hydration starts improving as GH-driven collagen synthesis kicks in. Facial flushing typically fades by now. Injection-site reactions still happen if sites aren't rotated consistently. Months 2 to 3: Body composition shifts become measurable. Vittone et al. [1] documented lean mass gains and fat reduction in age-advanced adults at this point. Community reports line up: modest fat loss around the midsection, improved muscle definition, better skin texture. Nail and hair growth may accelerate. Joint comfort tends to improve. Months 4 to 6: Peak benefit window for body composition, sleep, and recovery. IGF-1 plateaus at a new raised baseline. Skin thickness may increase based on clinical GHRH data. This is also where continuous (uncycled) users start noticing antibody-driven efficacy loss. If benefits suddenly plateau around month five or six and you haven't been cycling, antibody formation is the most likely explanation. Month 6 and beyond (with cycling): Appropriate cycling (5 days on, 2 days off, plus periodic four-week breaks) keeps pituitary sensitivity intact and slows antibody formation. No published RCTs extend past six months for anti-aging sermorelin use; long-term safety data is extrapolated from the pediatric GH deficiency literature. Community users who cycle report sustained benefits over multiple cycles spanning a year or more. Continuous non-cycled users report progressive non-response, sometimes reaching full loss of efficacy within 6 to 12 months. IGF-1 monitoring every three months is the standard approach for long-term protocols.
GH pulses begin normalizing within days. Pituitary somatotrophs require ~1–2 weeks of GHRH-R stimulation to upregulate GH secretory capacity. Plasma IGF-1 begins to rise.
Improved sleep depth and ease of falling asleep is the most consistently reported first effect. Vivid dreams common. Mild facial flushing 20–30 min post-injection.
IGF-1 measurably elevated above baseline. GH-driven protein synthesis and lipolysis beginning. Sleep architecture improvements consistent with GH effects on slow-wave (deep) sleep stages.
Reduced muscle soreness after workouts. More stable daytime energy and mood improvements reported. Facial flushing side effect typically resolving by this point.
Vittone et al. 1997 (PMID 9141536) showed measurable lean mass gains and fat reduction in age-advanced adults at 3 months of GHRH analog therapy. Skin collagen synthesis increases with sustained GH elevation.
Modest but noticeable fat loss around midsection. Improved muscle definition. Skin hydration and texture improving. Nail and hair growth may accelerate.
Peak benefits for body composition and sleep quality. IGF-1 reaches stable elevated baseline. Early bone mineral density improvement possible (full DEXA changes require 6+ months). Skin thickness increase documented in GHRH clinical data.
Most users report this as peak benefit period. Lean mass and fat loss most noticeable. Some users on continuous (uncycled) dosing begin noticing antibody-driven efficacy plateau around month 5–6.
Appropriate cycling (5-on/2-off; periodic 4-week breaks) mitigates antibody formation and maintains pituitary sensitivity. No published RCTs beyond 6 months for anti-aging use; long-term data extrapolated from GH deficiency literature.
Experienced cycled users report sustained benefits with periodic breaks. Continuous non-cycled users report progressive efficacy loss over 6–12 months, eventually reaching non-response.
Source: Geref product label and PK studies; IV t½ ~6-7 min, SC t½ ~11-12 min (reported as 10-20 min range)
Loading the interactive decay curve.
Sermorelin acetate received FDA approval in 1997 as Geref for diagnosing GH deficiency and treating pediatric GH deficiency. The manufacturer voluntarily discontinued it in 2008 for business and manufacturing reasons, not safety concerns. Sermorelin has a USP monograph and is legally compoundable through licensed 503A and 503B pharmacies in the United States with a valid clinician prescription. This is a meaningful regulatory advantage over most peptides, which lack compounding eligibility. Compounded sermorelin is widely available through telehealth platforms and anti-aging clinics at $175 to $225 per month via subscription models. Sublingual tablet formulations have appeared through some telehealth services at $79 to $139 per month, though no published pharmacokinetic data compares sublingual to subcutaneous bioavailability. Athletes should know that sermorelin falls under the WADA 2026 Prohibited List as a Growth Hormone Releasing Factor (S2.4). It is detectable and any athlete subject to anti-doping testing should not use it. This content is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
